Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. - Wikidata - wikimedia - TriplyDB

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

http://www.wikidata.org/entity/Q33747406

about

The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment Pharmacogenomics of breast cancer therapy: an update Genome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levels Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.DL-ADR: a novel deep learning model for classifying genomic variants into adverse drug reactions.A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent Gut microbiota-derived propionate reduces cancer cell proliferation in the liver Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.Lymphoma risk in systemic lupus: effects of disease activity versus treatment Effect of an education program on knowledge, self-care behavior and handwashing competence on prevention of febrile neutropenia among breast cancer patients receiving Doxorubicin and Cyclophosphamide in Chemotherapy Day Centre.Pharmacogenetics of genes across the doxorubicin pathway.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Pharmacogenetics of chemotherapy efficacy in breast cancer.Drug-induced oxidative stress and toxicity.Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.Pharmacogenetics of drugs used in the treatment of ocular inflammatory diseases.Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.Drug transporters in breast cancer: response to anthracyclines and taxanes.Nuclear receptors and drug metabolism for the personalization of cancer therapy.Pharmacogenomics and the treatment of acute myeloid leukemia.Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.Herceptin-decorated salinomycin-loaded nanoparticles for breast tumor targeting.Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy.The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Distinctiveness of the Roma population within CYP2B6 worldwide variation.Different transport activity of human triallelic MDR1 893Ala/Ser/Thr variant and its association with herb extracts.

P2860

Q26749954-88DC7736-6707-4F6E-A54A-2F7654B986C2 Q27006783-33023D19-6850-4611-8667-F2EA3FD0C9DC Q27324181-4FC7A66D-E546-4062-A0E2-50552DA863BB Q28083875-6BDBB380-6D57-4A43-8D26-FB4E5963D716 Q28552450-D3AAC469-3F4D-4F38-8D07-9EA130FED095 Q30418239-494427CA-6E5A-4652-BAF7-195F26FEBEB1 Q30584978-45E88827-3BAF-46D3-BC6A-9CCE534EE691 Q33591401-7B341631-5858-4FAF-94A7-6557C1324A27 Q34558816-434D1D0D-2569-4E96-8A83-7BC0B9F59EA0 Q36100724-FC837033-0C52-4DB9-BDC0-A50E0B4F87A9 Q36181844-F656E569-A639-4190-BED0-D1A9B59A06DD Q36236476-B7249F78-CC05-408F-9F25-9F3E6FF18353 Q36384257-3C2BA8E4-D7BD-40A4-87DC-96685BB23216 Q36387826-B02AFD93-CC1C-49F6-850F-9CEFD2FDFC07 Q36489727-B1062F87-1767-4490-9E75-1BBC8531968E Q36550926-C3B3EC95-E97C-4B8A-B899-8AE8262B20FF Q36652629-63C97987-AF4B-4F5D-8DBE-27FEAD29D77A Q36657589-C5A59999-E5F5-43FA-9D98-D6D2EFA8AB65 Q36948123-23917007-EA55-4EAD-8DD3-71DD43AE1AF3 Q37374458-173708F9-2D2B-4F20-823F-B7463E285797 Q37440949-A456FB7D-57BE-452C-8591-207F39E84657 Q37932556-6792B6FB-E978-4822-AC99-DAF32540A18A Q37939200-61E8462C-2AB4-4707-9B38-441ADAF7DD2A Q38003703-4620686D-F593-4735-B3C8-7F88213C71C4 Q38037517-97556096-156C-46BA-A8CD-BC96A7D1C3F7 Q38047337-4CC74361-4ADA-4E65-8C2C-4FAE4FD3DEE9 Q38063197-D35B275F-F8EB-49F2-8D7C-BD436D819577 Q38092131-E643B0A2-94BF-4C68-9A0E-FA4D6A011BFF Q38271855-E669BDFD-E26E-4052-86AD-C76718870340 Q38533459-25D68EF4-7B41-4F52-B891-19616C24B413 Q38575008-9F389C97-5B85-40F7-81BF-85C8CB727D6F Q38704025-9FEBCDAC-8314-48CA-A82F-466F3314723C Q38887034-4A29249F-D145-4A15-B11D-FC2ABD6674B5 Q38933314-5BF3BDE9-9BD6-40A8-A8F1-FFC002FA39BA Q39255407-869BAF10-CC4F-492E-B1C8-D90C1E76CEA7 Q40040202-DE9D307D-5E2A-4A6F-9DB3-D2E00783FC96 Q45924371-C3609CF8-B3E2-47CC-A840-5037D91F1ABB Q46250643-A225142D-7229-4D77-AF42-8204FFDA8B01 Q47670434-EF494A14-738A-4756-AE89-D13699148ADD Q48682180-4E3D62A5-60A1-4DB4-B77F-BE088D0660B6

P2860

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

http://www.wikidata.org/entity/Q33747406

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Influence of pharmacogenetics ...... orubicin and cyclophosphamide.

@ast

Influence of pharmacogenetics ...... orubicin and cyclophosphamide.

@en

type

label

Influence of pharmacogenetics ...... orubicin and cyclophosphamide.

@ast

Influence of pharmacogenetics ...... orubicin and cyclophosphamide.

@en

prefLabel

Influence of pharmacogenetics ...... orubicin and cyclophosphamide.

@ast

Influence of pharmacogenetics ...... orubicin and cyclophosphamide.

@en

P1433

Q33747406-62F159FC-C0D2-4E56-9E9E-5B28C6EB7FF8

P1476

Q33747406-BE7770E0-A010-4DF8-BA2A-1E3F7D01C1F1

P2093

Q33747406-128E291C-9B2D-4CC1-908F-65681445A3BF

Q33747406-7A13D243-9F75-4CF0-9F6E-984F7F011996

Q33747406-A0E321AE-A352-496D-875D-7BA47DB25A7A

Q33747406-F9814CA2-C17E-4353-8545-D2C066013896

Q33747406-FF3411C0-9DDF-4975-9494-BDC01A9EE684

P2860

Q33747406-0E3C36F9-3E48-471B-878F-6B4980F0A047

Q33747406-1996A26A-300E-4488-9E95-219388DE9EDD

Q33747406-1F54F657-5DF5-47EE-9C3D-434E43B91B60

Q33747406-24CED418-FAC3-49C8-99D4-E67469B32E61

Q33747406-385E585F-F81B-4F45-BB26-1D1D8DE8400F

Q33747406-479C8007-DB8F-474E-927B-D58C00370208

Q33747406-4D5EB1FF-18F5-428B-8B61-A7DC7C8F368F

Q33747406-6468179C-CD5C-437B-96E8-A7416D5C9350

Q33747406-6ABD4DBC-4556-46CA-85A9-6B64FF04CC00

Q33747406-7014371F-1B31-45D9-9D3A-34FF01942151

P2888

Q33747406-2A87DC37-7124-457E-A533-329E9E89CFDF

P304

Q33747406-F729E9AD-E9F0-4BB6-856E-FFE4795FE716

P31

Q33747406-B48EBF33-9D85-4416-A09F-340B49DE862E

P356

Q33747406-4B82FC9A-48F4-480E-B4EA-2D4D7FED7643

P407

Q33747406-59909E98-EAFD-40B3-90BB-099AE029AA81

P433

Q33747406-74B28570-8281-446C-8A12-B5EDAED47E59

P478

Q33747406-EDB52455-6E40-426D-996E-CDA9DADA34D9

P50

Q33747406-19E75562-53DF-49D1-AC8A-8D01C196E6C9

Q33747406-79D522CD-DC4E-425E-AB32-5E5DE789879D

P577

Q33747406-EACADF94-AF2E-4469-961C-6C87C5007ECC

P5875

Q33747406-AB2150D3-9E4D-47E9-8DB2-648E6E0F0D6A

P6179

Q33747406-49A8AA54-6F1C-410C-A0D8-606E56E2447D

P698

Q33747406-FFCED6F9-1BCC-4C3E-A9A5-CB4E4E5DBA00

P932

Q33747406-169D0064-5B3E-4D01-A647-D4C694AA8EE0

P356

P1433

British Journal of Cancer

P1476

Influence of pharmacogenetics ...... xorubicin and cyclophosphamide

@en

P2093

J Bray

http://www.w3.org/2001/XMLSchema#string

J Sludden

http://www.w3.org/2001/XMLSchema#string

M Cole

http://www.w3.org/2001/XMLSchema#string

M J Griffin

http://www.w3.org/2001/XMLSchema#string

M Verrill

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of the organic cation transporter SLC22A16: a doxorubicin importer

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans

Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3)

A "silent" polymorphism in the MDR1 gene changes substrate specificity

A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation.

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications.

Antimycotic drug discovery in the age of genomics.

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.

P2888

P304

1003-1009

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605587

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41548761

http://www.w3.org/2001/XMLSchema#string

P6179

1033281818

http://www.w3.org/2001/XMLSchema#string

P698

20179710

http://www.w3.org/2001/XMLSchema#string

P932

2844036

http://www.w3.org/2001/XMLSchema#string